ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2024
Mexican Health and Aging Study Biomarker and Genetic Data Profile.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the links between sleep quality and stroke risk in older adults.Scientific reports · 2025Article
- Evaluating the psychosocial effects of cancer on sleep quality and mental health in elderly populations.BMC psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The Mexican Health and Aging Study (MHAS) is one of the largest ongoing longitudinal studies of aging in Latin America, with six waves over 20 years. MHAS includes sociodemographic, economic, and health data from a nationally representative sample of adults 50 years and older in urban and rural Mexico. MHAS is designed to study the impact of diseases on adults' health, function, and mortality. As Mexico is experiencing rapid population aging, providing adequate information to study this phenomenon is vital for designing and implementing public policies. The availability of biomarker and genetic data and longitudinal survey data elevates opportunities for research on aging in a low-middle-income country. This manuscript describes the profile of biomarkers and genetic data available in the MHAS study, including sample sizes and sociodemographic characteristics of participants who provided biospecimens for biomarker analyses, emphasizing recent genetic data. The sample size of individuals with anthropometric biomarkers was 2 707 (Wave 1-2001), 2 361 (Wave 2-2003), 2 086 (Wave 3-2012), and 2 051 (2016). Capillary blood samples were collected from 2 063 participants in 2012 (Wave 3) and 1 141 in 2016. Venous blood samples for blood-based biomarkers were collected from 2 003 participants in 2012 (Wave 3) and 752 in 2016. Venous blood samples were also collected for genetic data from 2 010 participants in 2012 (Wave 3) and 750 in 2016. A total of 7 821 participants provided saliva in 2018, and 2 671 provided hair in 2018. From these samples, a total of 7 204 have genome-wide genetic data, 8 600 have apolipoprotein-E genotype data, and 7 156 have genetic ancestry data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.